Considering that LTED cells are assumed as a refractory model for endocrine therapy with aromatase inhibitor, our clinical results suggest the possible involvement of OCT1 in the endocrine resistance that might occur in breast cancer. This evidence concerns the gene POU2F1 and breast carcinoma.